|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar
|
|
2
|
Pulte D, Jansen L, Castro FA, Emrich K,
Katalinic A, Holleczek B and Brenner H; GEKID Cancer Survival
Working Group, : Trends in survival of multiple myeloma patients in
Germany and the United States in the first decade of the 21st
century. Br J Haematol. 171:189–196. 2015. View Article : Google Scholar
|
|
3
|
Cullis J: Haematology: Multiple myeloma.
Clin Med (Lond). 19:1882019. View Article : Google Scholar
|
|
4
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: A consensus of the International Myeloma Working
Group. Blood. 127:2955–2962. 2016. View Article : Google Scholar
|
|
5
|
Soekojo CY and Chng WJ: Treatment horizon
in multiple myeloma. Eur J Haematol. 109:425–440. 2022. View Article : Google Scholar
|
|
6
|
Burroughs Garcìa J, Eufemiese RA, Storti
P, Sammarelli G, Craviotto L, Todaro G, Toscani D, Marchica V and
Giuliani N: Role of 1q21 in multiple myeloma: From pathogenesis to
possible therapeutic targets. Cells. 10:13602021. View Article : Google Scholar
|
|
7
|
Hanamura I: Multiple myeloma with
High-risk cytogenetics and its treatment approach. Int J Hematol.
115:762–777. 2022. View Article : Google Scholar
|
|
8
|
D'Agostino M, Cairns DA, Lahuerta JJ,
Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D,
van de Donk NWCJ, et al: Second revision of the international
staging system (R2-ISS) for overall survival in multiple myeloma: A
european myeloma network (EMN) report within the HARMONY project. J
Clin Oncol. 40:3406–3418. 2022. View Article : Google Scholar
|
|
9
|
Hassan H and Szalat R: Genetic predictors
of mortality in patients with multiple myeloma. Appl Clin Genet.
14:241–254. 2021. View Article : Google Scholar
|
|
10
|
McBride A and Ryan PY: Proteasome
inhibitors in the treatment of multiple myeloma. Expert Rev
Anticancer Ther. 13:339–538. 2013. View
Article : Google Scholar
|
|
11
|
Smetana J, Berankova K, Zaoralova R, Nemec
P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S,
Zahradova L, et al: Gain(1)(q21) is an unfavorable genetic
prognostic factor for patients with relapsed multiple myeloma
treated with thalidomide but not for those treated with bortezomib.
Clin Lymphoma Myeloma Leuk. 13:123–130. 2013. View Article : Google Scholar
|
|
12
|
Sonneveld P, Schmidt-Wolf IG, van der Holt
B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E,
Broyl A, Blau IW, et al: Bortezomib induction and maintenance
treatment in patients with newly diagnosed multiple myeloma:
Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin
Oncol. 30:2946–2955. 2012. View Article : Google Scholar
|
|
13
|
An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie
Z, Sui W, Zhan F and Qiu L: Chromosome 1q21 gains confer inferior
outcomes in multiple myeloma treated with bortezomib but copy
number variation and percentage of plasma cells involved have no
additional prognostic value. Haematologica. 99:353–359. 2014.
View Article : Google Scholar
|
|
14
|
Chang H, Trieu Y, Qi X, Jiang NN, Xu W and
Reece D: Impact of cytogenetics in patients with relapsed or
refractory multiple myeloma treated with bortezomib: Adverse effect
of 1q21 gains. Leuk Res. 35:95–98. 2011. View Article : Google Scholar
|
|
15
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ. 339:b27002009.
View Article : Google Scholar
|
|
16
|
Wells GA, Shea BJ, O'Connell D, Peterson J
and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the
quality of non-randomized studies in meta-analysis. Sci Educ;
2000
|
|
17
|
Lee YH: An overview of meta-analysis for
clinicians. Korean J Intern Med. 33:277–283. 2018. View Article : Google Scholar
|
|
18
|
Li X, Chen W, Wu Y, Li J, Chen L, Fang B,
Feng Y, Liu J, Chen M, Gu J, et al: 1q21 Gain Combined with
High-risk factors is a heterogeneous prognostic factor in newly
diagnosed multiple myeloma: A multicenter study in China.
Oncologist. 24:e1132–e1140. 2019. View Article : Google Scholar
|
|
19
|
Schmidt TM, Barwick BG, Joseph N, Heffner
LT, Hofmeister CC, Bernal L, Dhodapkar MV, Gupta VA, Jaye DL, Wu J,
et al: Gain of Chromosome 1q is associated with early progression
in multiple myeloma patients treated with lenalidomide, bortezomib,
and dexamethasone. Blood Cancer J. 9:942019. View Article : Google Scholar
|
|
20
|
Du C, Mao X, Xu Y, Yan Y, Yuan C, Du X,
Liu J, Fan H, Wang Q, Sui W, et al: 1q21 gain but not t(4;14)
indicates inferior outcomes in multiple myeloma treated with
bortezomib. Leuk Lymphoma. 61:1201–1210. 2020. View Article : Google Scholar
|
|
21
|
Chen Q, Han X, Zheng G, Yang Y, Li Y,
Zhang E, Yang L, Dong M, He D, He J and Cai Z: The adverse impact
of a gain in chromosome 1q on the prognosis of multiple myeloma
treated with bortezomib-based regimens: A retrospective
single-center study in China. Front Oncol. 12:10846832022.
View Article : Google Scholar
|
|
22
|
Tang HKK, Fung CY, Morgan GJ, Kumar S, Siu
L, Ip HWA, Yip SF, Lau KNH, Lau CK, Lee H, et al: The impact of
bortezomib-based induction in newly diagnosed multiple myeloma with
chromosome 1q21 gain. Ther Adv Hematol. 13:204062072210820432022.
View Article : Google Scholar
|
|
23
|
Bisht K, Walker B, Kumar SK, Spicka I,
Moreau P, Martin T, Costa LJ, Richter J, Fukao T, Macé S, et al:
Chromosomal 1q21 abnormalities in multiple myeloma: A review of
translational, clinical research, and therapeutic strategies.
Expert Rev Hematol. 14:1099–1114. 2021. View Article : Google Scholar
|
|
24
|
Kumar SK, Dispenzieri A, Lacy MQ, Gertz
MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et
al: Continued improvement in survival in multiple myeloma: Changes
in early mortality and outcomes in older patients. Leukemia.
28:1122–1128. 2014. View Article : Google Scholar
|
|
25
|
Schmidt TM, Fonseca R and Usmani SZ:
Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J.
11:832021. View Article : Google Scholar
|
|
26
|
Rajkumar SV: Multiple myeloma: 2022 update
on diagnosis, risk stratification, and management. Am J Hematol.
97:1086–1107. 2022. View Article : Google Scholar
|
|
27
|
Shaughnessy JD Jr, Qu P, Usmani S, Heuck
CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, et
al: Pharmacogenomics of bortezomib test-dosing identifies
hyperexpression of proteasome genes, especially PSMD4, as novel
high-risk feature in myeloma treated with Total Therapy 3. Blood.
118:3512–3524. 2011. View Article : Google Scholar
|
|
28
|
Cao YJ, Zheng YH, Li Q, Zheng J, Ma LT,
Zhao CJ and Li T: MSC Senescence-related genes are associated with
myeloma prognosis and lipid metabolism-mediated resistance to
proteasome inhibitors. J Oncol. 2022:47056542022. View Article : Google Scholar
|
|
29
|
Walker BA, Mavrommatis K, Wardell CP,
Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A,
et al: A high-risk, Double-Hit, group of newly diagnosed myeloma
identified by genomic analysis. Leukemia. 33:159–170. 2019.
View Article : Google Scholar
|
|
30
|
Neben K, Lokhorst HM, Jauch A, Bertsch U,
Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K,
Pfreundschuh M, et al: Administration of bortezomib before and
after autologous stem cell transplantation improves outcome in
multiple myeloma patients with deletion 17p. Blood. 119:940–948.
2012. View Article : Google Scholar
|
|
31
|
Gao L, Liu Y, Li Y, Feng L, Wang Z, Wen L,
Wang F, Huang X, Lu J and Lai Y: The Importance of FISH Signal
Cut-off value and copy number variation for 1q21 in newly diagnosed
multiple myeloma: Is it underestimated? Clin Lymphoma Myeloma Leuk.
22:535–544. 2022. View Article : Google Scholar
|
